Navigation Links
GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology

AMSTERDAM, Netherlands, Sept. 25 /PRNewswire/ -- At the 2007 annual meeting of the European Association for the Study of Diabetes (EASD), the International Diabetes Federation (IDF) issued the new global diabetes guidelines of diabetes care which includes the management of postmeal glucose. These guidelines include the GlycoMark blood test as a new emerging technology to measure postmeal glucose.

In a released statement, the IDF indicated that the guideline emphasizes that people with diabetes should have their blood glucose levels closely monitored after meals in order to optimize diabetes control and reduce the risk of complications, particularly cardiovascular disease. This new approach to managing postmeal glucose will assist clinicians and organizations in developing effective strategies for managing diabetes.

"Diabetes is now recognized as one of the largest epidemics humanity has ever faced and a leading cause of death. It accounts for 3.8 million deaths per year, many of which are related to cardiovascular disease. This new advancement underscores the importance for people with diabetes and their healthcare providers to adopt all possible ways to better manage the disease," said Professor Stephen Colagiuri, Chair of the IDF Task Force on Clinical Guidelines.

The new IDF Guideline recommends that people with diabetes try to keep postmeal blood glucose levels to less than 7.8 mmol/l (140 mg/dl) two hours following a meal. IDF advises SMBG (self-monitoring of blood glucose) because it is the most practical method for measuring postmeal glucose and it allows people with diabetes to obtain "real-time" information about their glucose levels. This information enables people with diabetes and their healthcare providers to make timely adjustments in their treatment regimens to achieve and maintain their blood glucose levels within target. The guideline also includes the 1,5-anhydroglucitol blood test (GlycoMark) and continuous glucose monitoring (CGM) as emerging technologies for measuring postmeal glucose.

About GlycoMark

GlycoMark is an FDA approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5- AG) in blood. Multiple published studies in peer-reviewed journals have shown that the 1,5-AG test is a specific index of postprandial hyperglycemia (elevated after-meal glucose levels) and short-term glycemic control -- providing a useful complement to A1C testing. GlycoMark is being used in clinical practices nationwide and is available at major reference laboratories including Quest Diagnostics, LabCorp, Esoterix, Mayo Medical Laboratories, ARUP Laboratories, and Specialty Laboratories. The test is also available at most major contract research organizations for pharmaceutical research studies.

In a recent study published in the American Diabetes Association Diabetes Care journal (Dungan et al. Diabetes Care 2006; 29 (6): 1214-1219), it was shown that the GlycoMark 1,5-AG test reflected after-meal glucose levels more robustly than the A1C test. The study also showed that GlycoMark was able to reveal dramatically different after-meal glucose levels in patients with similar A1C levels.

Moreover, studies recently presented at the 67th Annual 2007 Scientific Sessions of the American Diabetes Association and other meetings show that GlycoMark is particularly valuable in detecting underlying treatment effects of agents such as exenatide (Byetta) and pramlintide (Symlin) which were not revealed by the gold standard hemoglobin A1C test. These findings have important implications for patient care and pharmaceutical research as the reduction of after-meal glucose rises is a key objective of diabetes drug therapy.

GlycoMark is being commercialized by a partnership between Toyota Tsusho America (New York, NY), Nippon Kayaku (Tokyo, Japan) and the BioMarker Group (Kannapolis, NC). GlycoMark activities are centered in the North Carolina Research Campus in Kannapolis, North Carolina, a 350-acre life sciences hub started by billionaire David H. Murdock.

More information about GlycoMark may be found at


1. Guideline for Management of Postmeal Glucose, International Diabetes

Federation, 20072.

2. Ceriello A, Postprandial Hyperglycemia and Diabetes Complications: Is

it Time to Treat? Diabetes 2005; 54(1):1-7

SOURCE BioMarker Group
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Infant receives first bloodless liver transplant
4. Spouses and other partners lower blood pressure says new research
5. H2O - a cure for low blood pressure
6. Uncontrolled blood pressure
7. Weight and Blood Pressure
8. Grandmother’s diet in pregnancy can affect grandchildren’s blood sugr
9. Early diagnosis for autism from blood tests may be possible
10. Antibiotic from crab blood indentified
11. Gum disease may be caused by blood clotting gene
Post Your Comments:
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ... company, Sublime Beauty NATURALS®. All products are available on Amazon or its webstore. ... organic facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," says ...
(Date:11/29/2015)... ... 2015 , ... NewsWatch featured X-wing as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... the future because flying cars are about to become a reality. Where’s the idea ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion from ... designed specially for Final Cut Pro X. FCPX users can now ... modification controls. Destoying and creating chaotic distortion is now quick and simple, putting ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Safe storage ... creativity of two inventors, one from Lakewood, New Jersey and the other from Bradley ... the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing all ... year? , This question has not been an easy question to answer. Especially when ... and the younger workforce don’t share the same discipline around working long hours. ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... -- The GE Health Cloud 1 was unveiled today at ... North America (RSNA) meeting in Chicago ... cloud ecosystem and its applications will connect radiologists and clinicians ... teams – both inside and outside the hospital setting. ... "As the digital industrial leader, we are betting big on ...
(Date:11/27/2015)... Une nouvelle approche consistant ... contre le cancer avancé.    --> ... au traitement photodynamique au Bremachlorin contre le cancer ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    Clinical Cancer Research . ...
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
Breaking Medicine Technology: